ClinicalTrials.govpublic full text
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
acute myeloid leukemia (aml), acute myeloid leukemia, venetoclax, gilteritinib, d5-pbcr, risk-stratified, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 831427
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.